Promotional price valid on web orders only. Your contract pricing may differ. Interested in signing up for a dedicated account number?
Learn More
  1. Home
  2. Products
  3. 5000391799

Medchemexpress LLC Sonidegib diphosphate | 1218778-77-8 | 99.9% | 681.49 | 5 MG
SDP

Catalog No. 5000391799
Encompass_Preferred

Sonidegib diphosphate, also known as Erismodegib diphosphate, is a potent and selective Smoothened (Smo) antagonist. It works by directly interacting with Smo to reduce the expression of downstream Hedgehog (Hh) signaling targets. This compound has shown dose-related antitumor activity in medulloblastoma mouse models, effectively inhibiting tumor growth and causing regression at higher doses. It is for research use only.

  • Potent and selective Smo antagonist
  • Interacts directly with Smo to reduce expression of downstream Hh signaling targets
  • Inhibits the Hh pathway in CD34+ chronic phase chronic myeloid leukemia (CML) cells
  • Reduces the number and self-renewal capacity of CML leukemia stem cells (LSC)
  • Demonstrates dose-related antitumor activity in medulloblastoma allograft mouse models
  • Significantly inhibits tumor growth and affords regression at higher doses

Catalog No. 50-003-91799 Supplier Medchemexpress LLC Supplier No. HY165825MG
May include imposed supplier surcharges.
Add to Cart
Add to Cart

missing translation for 'validMainframeMsg'

Sonidegib diphosphate, also known as Erismodegib diphosphate, is a potent and selective Smoothened (Smo) antagonist. It works by directly interacting with Smo to reduce the expression of downstream Hedgehog (Hh) signaling targets. This compound has shown dose-related antitumor activity in medulloblastoma mouse models, effectively inhibiting tumor growth and causing regression at higher doses. It is for research use only.

  • Potent and selective Smo antagonist
  • Interacts directly with Smo to reduce expression of downstream Hh signaling targets
  • Inhibits the Hh pathway in CD34+ chronic phase chronic myeloid leukemia (CML) cells
  • Reduces the number and self-renewal capacity of CML leukemia stem cells (LSC)
  • Demonstrates dose-related antitumor activity in medulloblastoma allograft mouse models
  • Significantly inhibits tumor growth and affords regression at higher doses

Product Title
Select an issue

By clicking Submit, you acknowledge that you may be contacted by Fisher Scientific in regards to the feedback you have provided in this form. We will not share your information for any other purposes. All contact information provided shall also be maintained in accordance with our Privacy Policy.